Gan & Lee Pharmaceuticals Co., Ltd.

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE100003ZH1
CNY
62.40
0.1 (0.16%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationQuarterly Results
Results Snapshot
YoYQoQ
Figures in Million
Consolidate Quarterly Results
Jun'25
Mar'25
Dec'24
Sep'24
Jun'24
Mar'24
Dec'23
Net Sales
1,072.34
975.80
791.49
922.31
746.38
554.07
696.04
Other Operating Income
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Total Operating income
1,072.34
975.80
791.49
922.31
746.38
554.07
696.04
Raw Material Cost
288.58
255.52
243.68
234.55
223.29
178.69
240.79
Purchase of Finished goods
0.00
0.00
0.00
0.00
0.00
0.00
0.00
(Increase) / Decrease In Stocks
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Employee Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Power Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Manufacturing Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Selling and Distribution Expenses
377.78
382.26
384.82
389.10
306.75
254.80
323.69
Other Expenses
12.33
11.96
12.61
12.55
12.25
12.23
12.07
Total Expenditure (Excl Depreciation)
789.64
757.43
754.64
749.16
652.54
555.76
685.20
Operating Profit (PBDIT) excl Other Income
282.7
218.4
36.9
173.1
93.80000000000001
-1.7000000000000002
10.8
Other Income
29.94
95.03
56.89
35.83
64.85
29.70
10.86
Operating Profit (PBDIT)
384.42
385.16
145.12
276.03
221.23
90.62
42.64
Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Exceptional Items
17.97
46.99
-11.29
13.78
68.63
85.50
-0.34
Gross Profit (PBDT)
783.76
720.28
547.81
687.75
523.09
375.38
455.24
Depreciation
71.76
71.76
67.05
67.05
62.56
62.56
57.41
Profit Before Tax
330.63
360.39
66.78
222.75
227.29
113.56
-4.88
Tax
38.87
48.47
-40.62
14.39
24.39
17.56
-78.64
Provisions and contingencies
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Profit After Tax
291.76
311.92
107.40
208.36
202.90
96.00
73.59
Extraordinary Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Net Profit
291.76
311.92
107.40
208.36
202.90
96.00
73.59
Share in Profit of Associates
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Minority Interest
0.00
0.00
0.00
0.00
-0.00
-0.00
0.16
Other related items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Consolidated Net Profit
291.76
311.92
107.40
208.36
202.90
96.00
73.76
Equity Capital
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Face Value
1.0
1.0
1.0
1.0
1.0
1.0
1.0
Reserves
10,965.23
11,312.12
11,054.47
11,206.86
10,977.09
10,842.59
10,742.51
Earnings per share (EPS)
0.49
0.53
0.18
0.35
0.34
0.16
0.13
Diluted Earnings per share
0.49
0.53
0.18
0.35
0.34
0.16
0.13
Operating Profit Margin (Excl OI)
26.36%
22.38%
2.68%
18.77%
12.57%
-0.3%
-3.68%
Gross Profit Margin
37.52%
44.29%
16.91%
31.42%
38.83%
31.79%
7.55%
PAT Margin
27.21%
31.97%
13.57%
22.59%
27.18%
17.33%
10.57%
Public Share Holdings (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Pledged Promotor Holding (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Quarterly Analysis Highlights - QoQ
stock-summary

Net Sales

QoQ Growth in quarter ended Jun 2025 is 9.89% vs 23.28% in Mar 2025

stock-summary

Consolidate Net Profit

QoQ Growth in quarter ended Jun 2025 is -6.44% vs 190.41% in Mar 2025

stock-summary

Operating Profit (PBDIT) excl Other Income

QoQ Growth in quarter ended Jun 2025 is 22.20% vs 228.91% in Mar 2025

stock-summary

Interest

No Interest in the last few periods

stock-summary

Operating Profit Margin (Excl OI)

QoQ Growth in quarter ended Jun 2025 has improved from Mar 2025

Compare Quarterly Results Of Gan & Lee Pharmaceuticals Co., Ltd. With
Markets Mojo
Figures in Million
Consolidate Quarterly Results
Markets Mojo
Markets Mojo
Change(CNY)
Change(%)
Net Sales
1,072.34
0
1,072.34
Other Operating Income
0.00
0.00
0.00
Total Operating income
1,072.34
0
1,072.34
Raw Material Cost
288.58
0
288.58
Purchase of Finished goods
0
0
0.00
(Increase) / Decrease In Stocks
0
0
0.00
Employee Cost
0.00
0
0.00
Power Cost
0
0
0.00
Manufacturing Expenses
0.00
0
0.00
Selling and Distribution Expenses
377.78
0
377.78
Other Expenses
12.33
0.00
12.33
Total Expenditure (Excl Depreciation)
789.64
0
789.64
Operating Profit (PBDIT) excl Other Income
282.70
0.00
282.70
Other Income
29.94
0
29.94
Operating Profit (PBDIT)
384.42
0
384.42
Interest
0.00
0
0.00
Exceptional Items
17.97
0
17.97
Gross Profit (PBDT)
783.76
0
783.76
Depreciation
71.76
0
71.76
Profit Before Tax
330.63
0
330.63
Tax
38.87
0
38.87
Provisions and contingencies
0
0
0.00
Profit After Tax
291.76
0
291.76
Extraordinary Items
0.00
0
0.00
Prior Period Expenses
0
0
0.00
Other Adjustments
0
0
0.00
Net Profit
291.76
0
291.76
Share in Profit of Associates
0
0
0.00
Minority Interest
0.00
0
0.00
Other related items
0.00
0.00
0.00
Consolidated Net Profit
291.76
0
291.76
Equity Capital
0
0
0.00
Face Value
1.00
0
0.00
Reserves
10,965.23
0
10,965.23
Earnings per share (EPS)
0.49
0
0.49
Diluted Earnings per share
0.49
0
0.49
Operating Profit Margin (Excl OI)
26.36%
0%
0.00
26.36%
Gross Profit Margin
37.52%
0%
0.00
37.52%
PAT Margin
27.21%
0%
0.00
27.21%
Public Share Holdings (%)
0%
0%
0.00
0.00%
Pledged Promotor Holding (%)
0%
0%
0.00
0.00%
Quarterly - Net Sales
Net Sales 107.23 Million
in Jun 2025

Figures in Million
stock-summary

QoQ Growth in quarter ended Jun 2025 is 9.89% vs 23.28% in Mar 2025

stock-summary

YoY Growth in quarter ended Jun 2025 is 43.66% vs 12.19% in Jun 2024

Quarterly - Consolidate Net Profit
Consolidate Net Profit 29.18 Million
in Jun 2025

Figures in Million
stock-summary

QoQ Growth in quarter ended Jun 2025 is -6.44% vs 190.41% in Mar 2025

stock-summary

YoY Growth in quarter ended Jun 2025 is 43.81% vs 138.99% in Jun 2024

Quarterly - Operating Profit (PBDIT)
Operating Profit (PBDIT) 35.45 Million
in Jun 2025

Figures in Million
stock-summary

QoQ Growth in quarter ended Jun 2025 is 22.20% vs 228.91% in Mar 2025

stock-summary

YoY Growth in quarter ended Jun 2025 is 126.66% vs 43.35% in Jun 2024

Quarterly - Interest
Markets Mojo
No Interest in the last few periods
Quarterly - Operating Profit Margin (Excl OI)
Operating Profit Margin (Excl OI) 26.36%
in Jun 2025

Figures in %
stock-summary

QoQ Growth in quarter ended Jun 2025 has improved from Mar 2025

stock-summary

YoY Growth in quarter ended Jun 2025 has improved from Jun 2024